Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients

Annals of Oncology

Volumn 11, Issue 6, 2000, Pages 685-690

  Haioun, C ^a   Besson, C ^a   Lepage, E ^a   Thieblemont, C ^b   Simon, D ^c   Rose, C ^d   Tilly, H ^e   Sonet, A ^f   Lederlin, P ^g   Attal, M ^h   Briere J ^c   Reyes, F ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d Groupement Hospitalier de L'Institut Catholique Facultél Libre de Méldecine de Lille   (France)

^e CENTRE HENRI BECQUEREL   (France)

^f Hôpital Mont Godinne   (France)

^g CHU NANCY BRABOIS   (France)

^h CHU PURPAN   (France)

Author keywords

Aggressive non Hodgkin's; CNS relapse; Meningeal prophylaxis; Methotrexate; Risk factors

Indexed keywords

CYTARABINE; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; STEROID;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM DISEASE; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; REGRESSION ANALYSIS; REMISSION; RISK FACTOR;

EID: 0033736141     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008394827806     Document Type: Article

References (25)

1. Central nervous system metastases from non-Hodgkin's lymphoma: Treatment and prophylaxis
2. Central nervous system involvement in patients with diffuse histiocytic and undifferentiated lymphoma/leukemia revisited
3. Central nervous system complications of non-Hodgkin's lymphoma. The potential role of prophylactic therapy
4. Involvement of the central nervous system in non-Hodgkin's lymphoma
5. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma
6. Central nervous system relapse in malignant lymphomas: Risk factors and implications for prophylaxis
7. Central nervous system involvement in non-Hodgkin's lymphoma: Analysis of 105 cases
8. Secondary central nervous system involvement by non-Hodgkin's lymphoma: The risk factors
9. Central nervous system relapse in non-Hodgkin's lymphoma
10. Risk factors, treatment, outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma
11. For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory?
12. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: The Bologna Experience
13. LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma
14. A randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma. The LNH87-1 study
15. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients
16. ECVB: A new high-dose CHOP regimen followed by an intensive consolidation in patients aged ≤60 years with aggressive lymphoma presenting with only one adverse prognostic factor of the international prognostic index. An interim analysis of the LNH93-2 protocol on 433 patients
17. Failure of first-line inductive high-dose chemotherapy in poor-risk patients with aggressive lymphoma updated results of the randomized LNH 93-3 study
18. Alternating does not improve results in poor prognosis aggressive lymphoma. LNH87-protocol group 3: A GELA study
19. A predictive model for aggressive non-Hodgkin's lymphoma. The International non-Hodgkin's lymphoma prognostic factors project
20. Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: A randomized study from the GELA
21. Therapy of Burkitt and B-cell acute lymphoblastic leukaemia and lymphoma: Experience with the LMB protocols of the SFOP in children and adults
22. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma
23. Testicular lymphoma: Late relapses and poor outcome despite doxorubicin-based therapy
24. Short intensive treatment with high-dose chemotherapy in patients with aggressive non-Hodgkin's lymphoma with 2 or 3 poor prognostic factors
25. Survival benefit of high-dose therapy over sequential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma. Final analysis of the prospective LNH87-2 protocol. A GELA study